Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) has seen a rise in its stock price by 8.83% in relation to its previous close of $36.26. However, the company has experienced a 5.42% gain in its stock price over the last five trading sessions. zacks.com reported 2025-06-30 that Ultragenyx Pharmaceuticals’ GTX-102 earns FDA Breakthrough status after early data shows sustained progress in Angelman syndrome patients.
Is It Worth Investing in Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Right Now?
Company’s 36-month beta value is 0.26.Analysts have differing opinions on the stock, with 13 analysts rating it as a “buy,” 6 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for RARE is 88.38M, and currently, short sellers hold a 6.88% ratio of that floaft. The average trading volume of RARE on July 03, 2025 was 1.05M shares.
RARE’s Market Performance
RARE’s stock has seen a 5.42% increase for the week, with a 9.19% rise in the past month and a 16.61% gain in the past quarter. The volatility ratio for the week is 5.50%, and the volatility levels for the past 30 days are at 4.22% for Ultragenyx Pharmaceutical Inc The simple moving average for the past 20 days is 5.94% for RARE’s stock, with a -8.98% simple moving average for the past 200 days.
Analysts’ Opinion of RARE
Goldman, on the other hand, stated in their research note that they expect to see RARE reach a price target of $67, previously predicting the price at $56. The rating they have provided for RARE stocks is “Buy” according to the report published on June 06th, 2024.
RBC Capital Mkts gave a rating of “Outperform” to RARE, setting the target price at $77 in the report published on April 22nd of the previous year.
RARE Trading at 7.61% from the 50-Day Moving Average
After a stumble in the market that brought RARE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -34.64% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RARE starting from Sanders Corazon (Corsee) D., who sale 2,405 shares at the price of $37.39 back on Jun 20 ’25. After this action, Sanders Corazon (Corsee) D. now owns 15,344 shares of Ultragenyx Pharmaceutical Inc, valued at $89,923 using the latest closing price.
Stock Fundamentals for RARE
Current profitability levels for the company are sitting at:
- -0.87 for the present operating margin
- 0.84 for the gross margin
The net margin for Ultragenyx Pharmaceutical Inc stands at -0.93. The total capital return value is set at -0.5. Equity return is now at value -386.33, with -41.97 for asset returns.
Based on Ultragenyx Pharmaceutical Inc (RARE), the company’s capital structure generated 0.21 points at debt to capital in total, while cash flow to debt ratio is standing at -10.19. The debt to equity ratio resting at 0.27. The interest coverage ratio of the stock is -8.35.
Currently, EBITDA for the company is -469.0 million with net debt to EBITDA at 0.2. When we switch over and look at the enterprise to sales, we see a ratio of 6.17. The receivables turnover for the company is 5.98for trailing twelve months and the total asset turnover is 0.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.40.
Conclusion
In a nutshell, Ultragenyx Pharmaceutical Inc (RARE) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
